KYMR Stock Overview
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Kymera Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.29 |
| 52 Week High | US$46.22 |
| 52 Week Low | US$13.15 |
| Beta | 1.71 |
| 1 Month Change | 26.86% |
| 3 Month Change | 12.02% |
| 1 Year Change | -20.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3.10% |
Recent News & Updates
Recent updates
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28
Kymera KT-333 gets FDA orphan drug status for blood cancer subtype
Sep 15Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces
Aug 15Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M
Aug 09Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Jul 04Kymera Therapeutics: A First Take
Feb 28Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth
Feb 28Kymera's Protein Degrader Platform Tech Moves Forward With 3rd Candidate; Updated Data On KT-474 In December At R&D Day
Nov 30Kymera: Targeting The Protein Degradation Space
Oct 22Analysts Just Shaved Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Forecasts Dramatically
Aug 08Kymera Therapeutics names Elaine Caughey as chief business officer
Jun 21Kymera Therapeutics presents new data demonstrating proof-of-degradation using E3 ligase
May 26Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are More Bearish Than They Used To Be
May 11Kymera posts positive preclinical data on IRAK4 degrader KT-474
May 10Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 08Kymera Therapeutics EPS misses by $0.14, misses on revenue
May 06Here's What Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shareholder Ownership Structure Looks Like
Mar 06Kymera Therapeutics Is A Protein Degrading Pioneer With A Triple-Figure Share Price In Waiting
Jan 14Here's What Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shareholder Ownership Structure Looks Like
Nov 21
Kymera's protein degradation programs show encouraging preclinical action in cancer
Nov 04Shareholder Returns
| KYMR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.3% | -0.5% | 1.6% |
| 1Y | -20.6% | 2.9% | -10.8% |
Return vs Industry: KYMR underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: KYMR underperformed the US Market which returned -10.8% over the past year.
Price Volatility
| KYMR volatility | |
|---|---|
| KYMR Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: KYMR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: KYMR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 169 | Nello Mainolfi | https://www.kymeratx.com |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc. Fundamentals Summary
| KYMR fundamental statistics | |
|---|---|
| Market Cap | US$2.04b |
| Earnings (TTM) | -US$153.84m |
| Revenue (TTM) | US$45.96m |
40.7x
P/S Ratio-12.2x
P/E RatioIs KYMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KYMR income statement (TTM) | |
|---|---|
| Revenue | US$45.96m |
| Cost of Revenue | US$158.64m |
| Gross Profit | -US$112.68m |
| Other Expenses | US$41.16m |
| Earnings | -US$153.84m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 23, 2023
| Earnings per share (EPS) | -2.82 |
| Gross Margin | -245.16% |
| Net Profit Margin | -334.72% |
| Debt/Equity Ratio | 0% |
How did KYMR perform over the long term?
See historical performance and comparison